NUVL Insider Trading
Insider Ownership Percentage: 12.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $233,053,197.08
Nuvalent Share Price & Price History
Current Price: $66.29
Price Change: ▲ Price Increase of +4.3 (6.94%)
As of 04/11/2025 05:00 PM ET
Nuvalent Insider Trading History
Nuvalent Institutional Trading History
Data available starting January 2016
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More on Nuvalent
Today's Range
Now: $66.29
52 Week Range
Now: $66.29
Volume
584,193 shs
Average Volume
476,387 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.43
Who are the company insiders with the largest holdings of Nuvalent?
Nuvalent's top insider shareholders include:
- James E Flynn (Director)
- Andrew A F Hack (Director)
- Matthew Shair (Director)
- James Richard Porter (CEO)
- Henry E Pelish (Insider)
- Alexandra Balcom (CFO)
- Darlene Noci (Insider)
- Deborah Ann Miller (Insider)
- Christopher Durant Turner (Insider)
- Emily Conley (Director)
- Anna Protopapas (Director)
Learn More about top insider investors at Nuvalent.
Who are the major institutional investors of Nuvalent?
Which institutional investors are buying Nuvalent stock?
In the last quarter, NUVL stock was purchased by institutional investors including:
- GAMMA Investing LLC
- Rhumbline Advisers